-
Case Report
-
Korean J Med. 2015;88(1):101-105. Published online January 1, 2015.
DOI: https://doi.org/10.3904/kjm.2015.88.1.101
- 췌장 신경 내분비종양에서 sunitinib과 고중성지방혈증
-
유상훈, 우인숙, 정윤화, 김교희, 조영윤, 한치화
-
가톨릭대학교 의과대학 내과학교실
- Hypertriglyceridemia Associated with Use of Sunitinib to Treat a Metastatic Pancreatic Neuroendocrine Tumor
-
Sanghoon Yoo, Insook Woo, Yun hwa Jung, Gyohui Kim, Youngyun Cho, Chi wha Han
-
Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Seoul, Korea
- Corresponding author: Chi wha Han ,Tel: +82-2-3779-2428, Fax: +82-2-780-3132, Email: cwhan@unitel.co.kr
- Received: January 8, 2014; Revised: March 27, 2014 Accepted: April 7, 2014.
-
- Abstract
- Sunitinib is a multi-target tyrosine kinase inhibitor used to treat gastrointestinal stromal tumors, renal cell carcinoma, and pancreatic neuroendocrine tumors. The most common adverse reactions are known to be nausea, fatigue, diarrhea, stomatitis, esophagitis, hypertension, skin toxicity (hand-foot syndrome), hypothyroidism, and reduction in the cardiac output of the left ventricle. Herein, we report the case of a 57 year-old female who visited our hospital complaining of epigastric pain. She had been taking sunitinib at 25 mg/day to treat a metastatic pancreatic neuroendocrine tumor. Upon computed tomography performed on admission, we observed that fluid had collected around the pancreas. Laboratory analysis revealed hypertriglyceridemia (triglycerides 993 mg/dL). Tyrosine kinase inhibitors are known to have limited effects on lipid metabolism. In this case, we suggest that hyperglycemia seems to have had a limited effect on lipid levels. We are rather of the view that hyperglycemia, a history of distal pancreatectomy, and hypothyrodisim, indirectly caused the observed hypertriglyceridemia.
Keywords :Sunitinib, Hypertriglyceridemia, Neuroendocrine tumor, Hypothyroidism
